A Placebo-Controlled Randomized Trial of Vigabatrin in the Management of Acute Alcohol Withdrawal

• Published in: Alcohol and alcoholism (Oxford) 2023-01, Vol.58 (1), p.40-45
• Main Authors: Williams, James, Collins, Lisa, Norman, Amanda, O'Neill, Helen, Lloyd-Jones, Martyn, Ogden, Edward, Bonomo, Yvonne, Pastor, Adam
• Format: Article
• Language: English
• Subjects: Alcoholism - drug therapy; Benzodiazepines - therapeutic use; Diazepam - adverse effects; Double-Blind Method; Humans; Substance Withdrawal Syndrome - drug therapy; Vigabatrin - adverse effects
• ISSN: 0735-0414; 1464-3502
• DOI: 10.1093/alcalc/agac044

To undertake a double blinded randomised placebo-controlled trial to assess the efficacy of vigabatrin, a GABA-transaminase inhibitor, as a benzodiazepine sparing agent in the management of acute alcohol withdrawal syndrome in a residential setting. We enrolled 120 patients with alcohol use disorder who were randomly assigned to either treatment with vigabatrin (2g/day for 4 days) or placebo. The primary outcome was defined as the number of participants in each treatment arm needing diazepam for withdrawal management. A secondary outcome prespecified was the total dose of diazepam received by participants in each treatment arm. Participants were recruited on admission to a residential withdrawal unit at St Vincent's Hospital Melbourne from December 2014 to April 2019. No significant difference was observed in the number of participants requiring benzodiazepines during their residential withdrawal stay with 44 participants (78.6%) in placebo arm requiring at least one dose of diazepam compared to 38 (66.7%) in vigabatrin arm (p = .156). An 18.1% difference was observed between the proportion of participants who received a total dose of >100mg of diazepam during their residential withdrawal stay in placebo arm (32.1%), compared to vigabatrin arm (14.0%, p = .022). There were higher rates of reported adverse events in placebo arm with nine (15.0%) participants reporting adverse events compared with two (3.3%) participants in vigabatrin arm (p = .027). Vigabatrin significantly reduced the number of participants requiring >100mg diazepam over the course of their alcohol withdrawal and was associated with a reduction in adverse effects when compared to placebo.